Psychiatry

Psychedelics set to be the revolutionary treatments in pscyhiatry - Thelansis Knowledge Partners

Retrieved on: 
Thursday, February 22, 2024
Knowledge, DSM-IV codes, Esketamine, TRD, Major depressive disorder, Drug development, TAS, USFDA, Psilocybin, MDMA, Psychiatry, CNS, Patient, Acute stress disorder, PTSD, Polypharmacy, Psychotherapy, MDD, KOL, Research, Central nervous system disease, Pharmaceutical industry

Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."

Key Points: 
  • Availability of psychedelic(s) with few administrations in a year and offering high remission rate could change the treatment pathway for these patients."
  • According to an interviewed U.S.-based neurologist by Thelansis – "We desperately need disease-modifying treatments for many neurodegenerative conditions.
  • As psychedelics would be beneficial for treatment-nonresponders or severe patients, the commercial opportunities are multiple for in-pipeline psychedelic therapies.
  • What is the probable opportunity for Psychedelics (e.g., psilocybin, MDMA) to address the unmet needs of other TAs?

EDCare Expands Eating Disorder Treatment Program in Omaha, Nebraska

Retrieved on: 
Thursday, February 22, 2024
Eating, PHP, Partial, Hope, Learning, Psychiatry, Prevalence, COVID-19, Helsinki University Central Hospital, Health, Patient, Eating disorder, Athlete, Housing, CO, Nursing

OMAHA, Neb., Feb. 22, 2024 /PRNewswire/ -- EDCare, a trusted leader in eating disorder treatment, is pleased to announce the expansion of its program in Omaha, Nebraska, with the introduction of its gender-inclusive Partial Hospitalization Program (PHP) designed for adults, ages 18 and older.

Key Points: 
  • OMAHA, Neb., Feb. 22, 2024 /PRNewswire/ -- EDCare, a trusted leader in eating disorder treatment, is pleased to announce the expansion of its program in Omaha, Nebraska, with the introduction of its gender-inclusive Partial Hospitalization Program (PHP) designed for adults, ages 18 and older.
  • EDCare expands to offer adult Partial Hospitalization Program for eating disorders in Omaha, NE.
  • The decision to expand EDCare's levels of care comes in response to the growing demand for specialized eating disorder treatment services within the community.
  • Their services also encompass specialized eating disorder treatment for athletes through Denver's unique Athlete EDGE® program.

The Inner Circle Acknowledges, Jose A. Matus as a Top Pinnacle Professional

Retrieved on: 
Monday, February 19, 2024
NCV, School, ABPN, Veterans Health Administration, Inner circle, Suite, Multimedia, Medical director, Skiing, Seizure, Rehabilitation hospital, American Medical Association, Texas Medical Association, BPN, Electrodiagnostic medicine, Internal medicine, Patient, Medicine, EMG, Psychiatry, Fellow, DSM-IV codes, American Academy

SHERMAN, Texas, Feb. 19, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Jose A. Matus is acknowledged as a Top Pinnacle Professional for his contributions to the field of neurology.

Key Points: 
  • SHERMAN, Texas, Feb. 19, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Jose A. Matus is acknowledged as a Top Pinnacle Professional for his contributions to the field of neurology.
  • Dr. Matus earned a medical degree from the School of Medicine at The Universidad de San Carlos de Guatemala in 1982.
  • He finished a Neurology Residency in 1995 at the Loma Linda University Medical Center in Loma Linda, CA.
  • Dr. Matus sees patients for acute neurology care and performs neuro-diagnostic procedures like EMG, NCV EEGs, and Carotid Ultrasounds.

Shamir Medical Center Reveals New Long-Term Results from Long COVID Study to Highlight Positive Impact on Symptoms Resulting from Hyperbaric Oxygen Therapy

Retrieved on: 
Thursday, February 15, 2024
Regeneration, Metabolism, Research, Randomized controlled trial, Tel Aviv University, Inflammation, Hyperbaric medicine, Quality of life, Neuron, Sleep, Psychiatry, Thrombosis, Shamir Medical Center, Cytokine, Fatigue, COVID, Patient, Gene, HBOT, Tissue, Pressure, Pharmaceutical industry

In a previous randomized controlled trial, significant improvements in cognitive, psychiatric, fatigue, sleep, and pain symptoms among long COVID patients who underwent a unique protocol of hyperbaric oxygen therapy were documented.

Key Points: 
  • In a previous randomized controlled trial, significant improvements in cognitive, psychiatric, fatigue, sleep, and pain symptoms among long COVID patients who underwent a unique protocol of hyperbaric oxygen therapy were documented.
  • This longitudinal follow-up included 31 patients from the original study, who were treated with 40 daily sessions of HBOT.
  • The results indicate HBOT can improve the quality of life, quality of sleep, psychiatric and pain symptoms of patients suffering from long COVID.
  • By delivering high oxygen concentrations, HBOT can enhance oxygen delivery to tissues, resulting in recovery of injured tissues permanent improvement.

Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024

Retrieved on: 
Wednesday, February 14, 2024
Fibromyalgia, Tonix Pharmaceuticals, FDA, Pain, Food, Sleep, Behavioral neuroscience, Hope, Hydrogen chloride, University, Fatigue, Patient, University of Cincinnati, University of Michigan, Psychiatry, Tablet, NDA, KOL, Pharmaceutical industry

CHATHAM, N.J., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, held a key opinion leader (KOL) webinar to discuss the positive Phase 3 data of Tonmya™ (also known as TNX-102 SL, cyclobenzaprine HCl sublingual tablets) for the management of fibromyalgia, and the path to file for FDA approval in the second half of 2024. The webinar was held on January 31, 2024 and hosted by Alliance Global Partners (A.G.P.).

Key Points: 
  • The webinar was held on January 31, 2024 and hosted by Alliance Global Partners (A.G.P.).
  • As previously announced, Tonix’s second positive Phase 3 study, RESILIENT, met its pre-specified primary endpoint, significantly reducing daily pain compared to placebo (p=0.00005) in participants with fibromyalgia.
  • Tonix plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2024 for Tonmya™ for the management of fibromyalgia.
  • “We are now an important step closer to bringing a new, first-line treatment to fibromyalgia patients that offers broad symptom relief and favorable tolerability for chronic use and adherence.”

Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 13, 2024
Mental Health, Research, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Momentum, Social anxiety disorder, Anxiety, SAD, Premenstrual dysphoric disorder, Psychiatry, Safety, Menopause, SUDS, Patient, DSM-IV codes, G&A, MDD, PMDD, NDA, Hot, Pharmaceutical industry

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended December 31, 2023 and provided a corporate update.

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended December 31, 2023 and provided a corporate update.
  • As of February 12, 2024, the Company had 27,029,731 shares of common stock issued and 3,577,240 pre-funded warrants outstanding.
  • Vistagen will host a conference call and live audio webcast this afternoon at 5:00 p.m. Eastern Time to provide a corporate update.
  • In addition, a telephone playback of the call will be available after approximately 8:00 p.m. Eastern Time on Tuesday, February 13, 2024.

Psychedelic Science 2025 – the Fifth and Largest Psychedelic Conference in History – Announced for June 16-20 2025 in Denver, Colorado

Retrieved on: 
Tuesday, February 13, 2024
SAN, MAPS, Research, Culture, Colorado Convention Center, Spirituality, Conference, Safety, History, Death, Policy, Energy, Medicine, PTSD, Science, Trauma, Movement, Former, Psychedelic drug, Psychiatry, Cancer, Nightclub

Psychedelic Science 2023, held this past June, boasted a record-breaking 22,000+ attendees -- 12,500 in-person and over 10,000 online through The Virtual Trip. Colorado Governor Jared Polis, Former Governor of Texas and US Secretary of Energy Rick Perry, Michael Pollan, Aaron Rodgers, and Melissa Etheridge were just a few of the speakers. The distinguished Dr. Roland Griffiths, professor of behavioral science and psychiatry and a pioneer in the advancement of psychedelic research, was also honored at the largest dinner event in the history of the Colorado Convention Center in one of his last public appearances before his death from cancer in October.

Key Points: 
  • SAN JOSE, Calif. , Feb. 13, 2024 (GLOBE NEWSWIRE) -- The Multidisciplinary Association for Psychedelic Studies ( MAPS ) has announced that the Psychedelic Science 2025 Conference will convene in the city of Denver June 16–20, 2025, at the Colorado Convention Center.
  • This is the fifth edition of the Psychedelic Science conference series, hosted by MAPS.
  • Programming will explore the full spectrum of psychedelics, including science, medicine, policy, business, spirituality, and culture.
  • Psychedelic Science 2023, held this past June, boasted a record-breaking 22,000+ attendees -- 12,500 in-person and over 10,000 online through The Virtual Trip .

Vive Concierge, Inc. Announces Groundbreaking Expansion into Mental Health Services with Dr. Charles Sophy at the Helm

Retrieved on: 
Tuesday, February 13, 2024
Concierge medicine, Hospital, Mental health, Vive, Kaiser, Government, Emergency medicine, University, Family, CNN, Mental, Wellness, Pediatrics, Kaiser Family Foundation, Psychiatry, Nursing

Vive Concierge expands into mental health with Dr. Charles Sophy leading, focusing on underserved LA communities.

Key Points: 
  • Vive Concierge expands into mental health with Dr. Charles Sophy leading, focusing on underserved LA communities.
  • Dr. Charles Sophy, a distinguished psychiatrist with over 35 years experience, joins Vive Concierge as the Head of Mental Health and Wellness.
  • "Amidst a national mental health crisis, our mission at Vive Concierge is more vital than ever.
  • The introduction of mental health services is a key component of Vive Concierge's innovative Vive Care Connect platform, which revolutionizes care coordination and patient engagement.

Silver Creek Pharmaceuticals Appoints Mark Corrigan, M.D. As President

Retrieved on: 
Monday, February 12, 2024
Cornell University, Acquisition, SAN, Sunovion, Merck, Research, Pharmacia & Upjohn, MD, Drug development, Growth, Research and development, University, Ōtsuka, Therapy, Advanz Pharma, Psychiatry, Development, Cell, Medical research, Pharmaceutical industry

SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Silver Creek Pharmaceuticals, a clinical-stage biotechnology company focused on the selective targeting of naturally-occurring growth factors to promote cell survival and growth, has appointed Mark Corrigan, MD, as President.

Key Points: 
  • Dr. Corrigan brings over three decades of life sciences leadership experience to Silver Creek.
  • SAN FRANCISCO, Feb. 12, 2024 /PRNewswire/ -- Silver Creek Pharmaceuticals, a clinical-stage biotechnology company focused on the selective targeting of naturally-occurring growth factors to promote cell survival and growth, has appointed Mark Corrigan, MD, as President.
  • "We are pleased to welcome Dr. Corrigan to lead Silver Creek through its next phase of growth," said Tim Throsby, Silver Creek's Chairman of the Board.
  • "The elegance and innovation behind Silver Creek's Smart Growth Factor™ platform is very compelling, and the pre-clinical data around scp776 is equally impressive.

The Howard and Georgeanna Jones Foundation for Reproductive Medicine announces its sponsorship of the Jones Foundation Infertility Counseling Conference

Retrieved on: 
Monday, February 12, 2024
Gynaecology, Public policy, Mental health, Reproductive medicine, Thomas Jefferson University, Clinical professor, Learning, Conference, Obstetrics, Georgetown University Law Center, Psychiatry, Nursing

VIRGINIA BEACH, Va., Feb. 12, 2024 /PRNewswire/ -- The Howard and Georgeanna Jones Foundation for Reproductive Medicine is pleased to announce that it has become the primary sponsor of the internationally acclaimed Jones Foundation Infertility Counseling Conference ("JFICC"), formerly known as the Jefferson Infertility Counseling Conference.

Key Points: 
  • VIRGINIA BEACH, Va., Feb. 12, 2024 /PRNewswire/ -- The Howard and Georgeanna Jones Foundation for Reproductive Medicine is pleased to announce that it has become the primary sponsor of the internationally acclaimed Jones Foundation Infertility Counseling Conference ("JFICC"), formerly known as the Jefferson Infertility Counseling Conference.
  • As one of its long-established missions of sponsoring educational endeavors to address public policy issues impacting reproductive medicine and contribute to improving the human condition, the Jones Foundation is excited to sponsor this exceptional educational conference.
  • This 4-day annual conference is attended by over 250 professionals from the United States and Europe.
  • Long recognized as the premier annual conference for mental health and allied professionals practicing in the assisted reproductive technology space, the annual conference will be held April 17-20, 2024, in Philadelphia, PA.